Abbaszadeh Z, Çeşmeli S, Biray Avcı Ç. Essential gamers in glycolysis: most cancers progress. Gene. 2020;726: 144158.
Shin E, Koo JS. Glucose metabolism and glucose transporters in breast most cancers. Entrance Cell Dev Biol. 2021;9:728759–728759.
DeBerardinis RJ, Chandel NS. We have to discuss concerning the Warburg impact. Nat Metab. 2020;2:127–9.
Kumar A, Singh M, Sharma D, Kumar V, Rani R. Tumor metabolism: centered on tumor glycolysis, progress, and prospects in most cancers remedy. In: Abraham DJ, editor. Burger’s medicinal chemistry and drug discovery. Hoboken: Wiley; 2003. p. 1–33. https://doi.org/10.1002/0471266949.bmc286.
Liberti MV, Locasale JW. The Warburg impact: how does it profit most cancers cells? Traits Biochem Sci. 2016;41:211–8.
Reinfeld BI, Rathmell WK, Kim TK, Rathmell JC. The therapeutic implications of immunosuppressive tumor cardio glycolysis. Cell Mol Immunol. 2022;19:46–58.
Wu Q, Yu X, Li J, Solar S, Tu Y. Metabolic regulation within the immune response to most cancers. Most cancers Commun. 2021;41:661–94.
Lin X, Xiao Z, Chen T, Liang SH, Guo H. Glucose metabolism on tumor plasticity, analysis, and remedy. Entrance Oncol. 2020;10:317.
El Hassouni B, Granchi C, Vallés-Martí A, Supadmanaba IGP, Bononi G, Tuccinardi T, Funel N, Jimenez CR, Peters GJ, Giovannetti E, Minutolo F. The dichotomous position of the glycolytic metabolism pathway in most cancers metastasis: Interaction with the advanced tumor microenvironment and novel therapeutic methods. Semin Most cancers Biol. 2020;60:238–48.
Porporato PE, Dhup S, Dadhich RK, Copetti T, Sonveaux P. Anticancer targets within the glycolytic metabolism of tumors: a complete evaluate. Entrance Pharmacol. 2011;2:49–49.
Talekar M, Boreddy SR, Singh A, Amiji M. Tumor cardio glycolysis: new insights into therapeutic methods with focused supply. Skilled Opin Biol Ther. 2014;14:1145–59.
Yu L, Chen X, Solar X, Wang L, Chen S. The glycolytic change in tumors: what number of gamers are concerned? J Most cancers. 2017;8:3430–40.
Prasad CP, Gogia A, Batra A. Important position of cardio glycolysis in epithelial-to-mesenchymal transition throughout carcinogenesis. Clin Transl Oncol. 2022;24:1844–55.
Martínez-Reyes I, Chandel NS. Most cancers metabolism: trying ahead. Nat Rev Most cancers. 2021;21:669–80.
Sheng H, Tang W. Glycolysis inhibitors for anticancer remedy: a evaluate of latest patents: latest pat anti-cancer. Drug Discov. 2016;11:297–308.
Akins NS, Nielson TC, Le HV. Inhibition of glycolysis and glutaminolysis: an rising drug discovery strategy to fight most cancers. Curr Prime Med Chem. 2018;18:494–504.
Tu B, Gao Y, Solar F, Shi M, Huang Y. Lipid metabolism regulation based mostly on nanotechnology for enhancement of tumor immunity. Entrance Pharmacol. 2022;13: 840440.
Yang B, Shi J. Chemistry of superior nanomedicines in most cancers cell metabolism regulation. Adv Sci. 2020;7:2001388.
Feher J. 2.9 – ATP manufacturing I: glycolysis. In: Feher J, editor. Quantitative human physiology. 2nd ed. Boston: Educational Press; 2017. p. 218–26. https://doi.org/10.1016/B978-0-12-800883-6.00020-3.
Lin L, Chen H, Zhao R, Zhu M, Nie G. Nanomedicine targets iron metabolism for most cancers remedy. Most cancers Sci. 2022;113:828–37.
Nagao A, Kobayashi M, Koyasu S, Chow CCT, Harada H. HIF-1-dependent reprogramming of glucose metabolic pathway of most cancers cells and its therapeutic significance. Int J Mol Sci. 2019;20:238.
Hay N. Reprogramming glucose metabolism in most cancers: can it’s exploited for most cancers remedy? Nat Rev Most cancers. 2016;16:635–49.
Liu Y, Xiang D, Zhang H, Yao H, Wang Y. Hypoxia-inducible factor-1: a possible goal to deal with acute lung damage. Oxid Med Cell Longev. 2020;2020:8871476–8871476.
Yu L, Chen X, Wang L, Chen S. The candy entice in tumors: cardio glycolysis and potential targets for remedy. Oncotarget. 2016;7:38908–26.
Ebert BL, Firth JD, Ratcliffe PJ. Hypoxia and mitochondrial inhibitors regulate expression of glucose transporter-1 through distinct cis-acting sequences. J Biol Chem. 1995;270:29083–9.
Mathupala SP, Rempel A, Pedersen PL. Glucose catabolism in most cancers cells: identification and characterization of a marked activation response of the kind II hexokinase gene to hypoxic circumstances. J Biol Chem. 2001;276:43407–12.
Denko NC. Hypoxia, HIF1 and glucose metabolism within the stable tumour. Nat Rev Most cancers. 2008;8:705–13.
Rempel A, Mathupala SP, Griffin CA, Hawkins AL, Pedersen PL. Glucose catabolism in most cancers cells: amplification of the gene encoding sort II hexokinase. Most cancers Res. 1996;56:2468–71.
Kim JW, Tchernyshyov I, Semenza GL, Dang CV. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic change required for mobile adaptation to hypoxia. Cell Metab. 2006;3:177–85.
Kluza J, Corazao-Rozas P, Touil Y, Jendoubi M, Maire C, Guerreschi P, Jonneaux A, Poll C, Balayssac S, Valable S, et al. Inactivation of the HIF-1α/PDK3 signaling axis drives melanoma towards mitochondrial oxidative metabolism and potentiates the therapeutic exercise of pro-oxidants. Can Res. 2012;72:5035–47.
Dang CV, Kim JW, Gao P, Yustein J. The interaction between MYC and HIF in most cancers. Nat Rev Most cancers. 2008;8:51–6.
Bao X, Zhang J, Huang G, Yan J, Xu C, Dou Z, Solar C, Zhang H. The crosstalk between HIFs and mitochondrial dysfunctions in most cancers growth. Cell Dying Dis. 2021;12:215.
Golias T, Kery M, Radenkovic S, Papandreou I. Microenvironmental management of glucose metabolism in tumors by regulation of pyruvate dehydrogenase. Int J Most cancers. 2019;144:674–86.
Kung-Chun Chiu D, Pui-Wah Tse A, Legislation C-T, Ming-Jing XuI, Lee D, Chen M, Equipment-Ho Lai R, Wai-Hin Yuen V, Wing-Sum Cheu J, Wai-Hung Ho D, et al. Hypoxia regulates the mitochondrial exercise of hepatocellular carcinoma cells by HIF/HEY1/PINK1 pathway. Cell Dying Dis. 2019;10:934.
Fukuda R, Zhang H, Kim JW, Shimoda L, Dang CV, Semenza GL. HIF-1 regulates cytochrome oxidase subunits to optimize effectivity of respiration in hypoxic cells. Cell. 2007;129:111–22.
Chan SY, Zhang Y-Y, Hemann C, Mahoney CE, Zweier JL, Loscalzo J. MicroRNA-210 controls mitochondrial metabolism throughout hypoxia by repressing the iron-sulfur cluster meeting proteins ISCU1/2. Cell Metab. 2009;10:273–84.
Anton L, DeVine A, Polyak E, Olarerin-George A, Brown AG, Falk MJ, Elovitz MA. HIF-1α stabilization will increase miR-210 eliciting first trimester extravillous trophoblast mitochondrial dysfunction. Entrance Physiol. 2019;10:699.
Lu Y. Meeting and switch of iron-sulfur clusters within the plastid. Entrance Plant Sci. 2018;9:336.
Zhang H, Gao P, Fukuda R, Kumar G, Krishnamachary B, Zeller KI, Dang CV, Semenza GL. HIF-1 inhibits mitochondrial biogenesis and mobile respiration in VHL-deficient renal cell carcinoma by repression of C-MYC exercise. Most cancers Cell. 2007;11:407–20.
Nowak N, Kulma A, Gutowicz J. Up-regulation of key glycolysis proteins in most cancers growth. Open Life Sci. 2018;13:569–81.
Peng Y, Wang Y, Zhou C, Mei W, Zeng C. PI3K/Akt/mTOR pathway and its position in most cancers therapeutics: are we making headway? Entrance Oncol. 2022;12: 819128.
Hoxhaj G, Manning BD. The PI3K-AKT community on the interface of oncogenic signalling and most cancers metabolism. Nat Rev Most cancers. 2020;20:74–88.
Du Z, Lovly CM. Mechanisms of receptor tyrosine kinase activation in most cancers. Mol Most cancers. 2018;17:58.
Ran C, Liu H, Hitoshi Y, Israel MA. Proliferation-independent management of tumor glycolysis by PDGFR-mediated AKT activation. Most cancers Res. 2013;73:1831–43.
Makinoshima H, Takita M, Saruwatari Ok, Umemura S, Obata Y, Ishii G, Matsumoto S, Sugiyama E, Ochiai A, Abe R, et al. Signaling by the phosphatidylinositol 3-kinase (PI3K)/mammalian goal of rapamycin (mTOR) axis is answerable for cardio glycolysis mediated by glucose transporter in epidermal development issue receptor (EGFR)-mutated lung adenocarcinoma. J Biol Chem. 2015;290:17495–504.
Salani B, Ravera S, Amaro A, Salis A, Passalacqua M, Millo E, Damonte G, Marini C, Pfeffer U, Sambuceti G, et al. IGF1 regulates PKM2 operate by Akt phosphorylation. Cell Cycle. 2015;14:1559–67.
Li W, Peng C, Lee MH, Lim D, Zhu F, Fu Y, Yang G, Sheng Y, Xiao L, Dong X, et al. TRAF4 is a essential molecule for Akt activation in lung most cancers. Most cancers Res. 2013;73:6938–50.
Barthel A, Okino ST, Liao J, Nakatani Ok, Li J, Whitlock JP Jr, Roth RA. Regulation of GLUT1 gene transcription by the serine/threonine kinase Akt1. J Biol Chem. 1999;274:20281–6.
Fan H, Wu Y, Yu S, Li X, Wang A, Wang S, Chen W, Lu Y. Vital position of mTOR in regulating cardio glycolysis in carcinogenesis (evaluate). Int J Oncol. 2021;58:9–19.
Magaway C, Kim E, Jacinto E. Concentrating on mTOR and metabolism in most cancers: classes and improvements. Cells. 2019;8:1584.
Huang L, Guo Z, Wang F, Fu L. KRAS mutation: from undruggable to druggable in most cancers. Sign Transduct Goal Ther. 2021;6:386.
Mukhopadhyay S, Vander Heiden MG, McCormick F. The metabolic panorama of RAS-driven cancers from biology to remedy. Nat Most cancers. 2021;2:271–83.
Hu Y, Lu W, Chen G, Wang P, Chen Z, Zhou Y, Ogasawara M, Trachootham D, Feng L, Pelicano H, et al. Ok-ras(G12V) transformation results in mitochondrial dysfunction and a metabolic change from oxidative phosphorylation to glycolysis. Cell Res. 2012;22:399–412.
Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg impact: the metabolic necessities of cell proliferation. Science. 2009;324:1029–33.
Lunt SY, Heiden MGV. Cardio glycolysis: assembly the metabolic necessities of cell proliferation. Annu Rev Cell Dev Biol. 2011;27:441–64.
Hirschhaeuser F, Sattler UGA, Mueller-Klieser W. Lactate: a metabolic key participant in most cancers. Can Res. 2011;71:6921–5.
Heydarzadeh S, Moshtaghie AA, Daneshpoor M, Hedayati M. Regulators of glucose uptake in thyroid most cancers cell strains. Cell Commun Sign. 2020;18:83.
DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of most cancers: metabolic reprogramming fuels cell development and proliferation. Cell Metab. 2008;7:11–20.
Yang Y, Ishak Gabra MB, Hanse EA, Lowman XH, Tran TQ, Li H, Milman N, Liu J, Reid MA, Locasale JW, et al. MiR-135 suppresses glycolysis and promotes pancreatic most cancers cell adaptation to metabolic stress by focusing on phosphofructokinase-1. Nat Commun. 2019;10:809.
Sousa CM, Kimmelman AC. The advanced panorama of pancreatic most cancers metabolism. Carcinogenesis. 2014;35:1441–50.
Yang J, Ren B, Yang G, Wang H, Chen G, You L, Zhang T, Zhao Y. The enhancement of glycolysis regulates pancreatic most cancers metastasis. Cell Mol Life Sci. 2020;77:305–21.
Brabletz T, Kalluri R, Nieto MA, Weinberg RA. EMT in most cancers. Nat Rev Most cancers. 2018;18:128–34.
Liu QL, Luo M, Huang C, Chen HN, Zhou ZG. Epigenetic regulation of epithelial to mesenchymal transition within the most cancers metastatic cascade: implications for most cancers remedy. Entrance Oncol. 2021;11: 657546.
Kalluri R, Weinberg RA. The fundamentals of epithelial–mesenchymal transition. J Clin Make investments. 2009;119:1420–8.
Cai H, Li J, Zhang Y, Liao Y, Zhu Y, Wang C, Hou J. LDHA promotes oral squamous cell carcinoma development by facilitating glycolysis and epithelial-mesenchymal transition. Entrance Oncol. 2019;9:1446.
Yetkin-Arik B, Vogels IMC, Nowak-Sliwinska P, Weiss A, Houtkooper RH, Van Noorden CJF, Klaassen I, Schlingemann RO. The position of glycolysis and mitochondrial respiration within the formation and functioning of endothelial tip cells throughout angiogenesis. Sci Rep. 2019;9:12608.
Cruys B, Wong BW, Kuchnio A, Verdegem D, Cantelmo AR, Conradi LC, Vandekeere S, Bouché A, Cornelissen I, Vinckier S, et al. Glycolytic regulation of cell rearrangement in angiogenesis. Nat Commun. 2016;7:12240.
Jang H, Yang J, Lee E, Cheong J-H. Metabolism in embryonic and most cancers stemness. Arch Pharmacal Res. 2015;38:381–8.
Shen Y-A, Wang C-Y, Hsieh Y-T, Chen Y-J, Wei Y-H. Metabolic reprogramming orchestrates most cancers stem cell properties in nasopharyngeal carcinoma. Cell Cycle. 2015;14:86–98.
Sancho P, Barneda D, Heeschen C. Hallmarks of most cancers stem cell metabolism. Br J Most cancers. 2016;114:1305–12.
Zhang W, Wang G, Xu ZG, Tu H, Hu F, Dai J, Chang Y, Chen Y, Lu Y, Zeng H, et al. Lactate is a pure suppressor of RLR signaling by focusing on MAVS. Cell. 2019;178:176-189.e115.
Jiang QX. Structural variability within the RLR-MAVS pathway and delicate detection of viral RNAs. Med Chem. 2019;15:443–58.
Rehwinkel J, Gack MU. RIG-I-like receptors: their regulation and roles in RNA sensing. Nat Rev Immunol. 2020;20:537–51.
Wu Y, Wu X, Wu L, Wang X, Liu Z. The anticancer features of RIG-I-like receptors, RIG-I and MDA5, and their purposes in most cancers remedy. Transl Res. 2017;190:51–60.
Bertrand F, Rochotte J, Colacios C, Montfort A, Tilkin-Mariamé A-F, Touriol C, Rochaix P, Lajoie-Mazenc I, Andrieu-Abadie N, Levade T, et al. Blocking tumor necrosis issue α enhances CD8 T-cell-dependent immunity in experimental melanoma. Can Res. 2015;75:2619–28.
Fisher DT, Appenheimer MM, Evans SS. The 2 faces of IL-6 within the tumor microenvironment. Semin Immunol. 2014;26:38–47.
Somarribas Patterson LF, Vardhana SA. Metabolic regulation of the cancer-immunity cycle. Traits Immunol. 2021;42:975–93.
Zhu Y, An X, Zhang X, Qiao Y, Zheng T, Li X. STING: a grasp regulator within the cancer-immunity cycle. Mol Most cancers. 2019;18:152.
Li J, Wang L, Chen X, Li L, Li Y, Ping Y, Huang L, Yue D, Zhang Z, Wang F, et al. CD39/CD73 upregulation on myeloid-derived suppressor cells through TGF-β-mTOR-HIF-1 signaling in sufferers with non-small cell lung most cancers. OncoImmunology. 2017;6: e1320011.
Tak E, Jung DH, Kim SH, Park GC, Jun DY, Lee J, Jung BH, Kirchner VA, Hwang S, Track GW, Lee SG. Protecting position of hypoxia-inducible factor-1α-dependent CD39 and CD73 in fulminant acute liver failure. Toxicol Appl Pharmacol. 2017;314:72–81.
Vijayan D, Younger A, Teng MWL, Smyth MJ. Concentrating on immunosuppressive adenosine in most cancers. Nat Rev Most cancers. 2017;17:709–24.
Leone RD, Emens LA. Concentrating on adenosine for most cancers immunotherapy. J Immunother Most cancers. 2018;6:57.
Cascone T, McKenzie JA, Mbofung RM, Punt S, Wang Z, Xu C, Williams LJ, Wang Z, Bristow CA, Carugo A, et al. Elevated tumor glycolysis characterizes immune resistance to adoptive T cell remedy. Cell Metab. 2018;27:977-987.e974.
Wang JX, Choi SYC, Niu X, Kang N, Xue H, Killam J, Wang Y. Lactic acid and an acidic tumor microenvironment suppress anticancer immunity. Int J Mol Sci. 2020;21:8363.
Mu X, Shi W, Xu Y, Xu C, Zhao T, Geng B, Yang J, Pan J, Hu S, Zhang C, et al. Tumor-derived lactate induces M2 macrophage polarization through the activation of the ERK/STAT3 signaling pathway in breast most cancers. Cell Cycle. 2018;17:428–38.
Angelin A, Gil-de-Gómez L, Dahiya S, Jiao J, Guo L, Levine MH, Wang Z, Quinn WJ third, Kopinski PK, Wang L, et al. Foxp3 reprograms T cell metabolism to operate in low-glucose, high-lactate environments. Cell Metab. 2017;25:1282-1293.e1287.
Kaymak I, Williams KS, Cantor JR, Jones RG. Immunometabolic interaction within the tumor microenvironment. Most cancers Cell. 2021;39:28–37.
Johnson MO, Wolf MM, Madden MZ, Andrejeva G, Sugiura A, Contreras DC, Maseda D, Liberti MV, Paz Ok, Kishton RJ, et al. Distinct regulation of Th17 and Th1 cell differentiation by glutaminase-dependent metabolism. Cell. 2018;175:1780-1795.e1719.
Van den Bossche J, O’Neill LA, Menon D. Macrophage immunometabolism: the place are we (going)? Traits Immunol. 2017;38:395–406.
Yang J, Yang Y-W. Steel-organic frameworks for biomedical purposes. Small. 2020;16:1906846.
Al Sharabati M, Sabouni R, Husseini GA. Biomedical purposes of metal-organic frameworks for illness analysis and drug supply: a evaluate. Nanomaterials (Basel). 2022;12:7004–20.
Abdelhamid HN. Zeolitic imidazolate frameworks (ZIF-8) for biomedical purposes: a evaluate. Curr Med Chem. 2021;28:7023–75.
Feng S, Zhang X, Shi D, Wang Z. Zeolitic imidazolate framework-8 (ZIF-8) for drug supply: a essential evaluate. Entrance Chem Sci Eng. 2021;15:221–37.
Zheng H, Zhang Y, Liu L, Wan W, Guo P, Nyström AM, Zou X. One-pot synthesis of metal-organic frameworks with encapsulated goal molecules and their purposes for managed drug supply. J Am Chem Soc. 2016;138:962–8.
Yan J, Liu C, Wu Q, Zhou J, Xu X, Zhang L, Wang D, Yang F, Zhang H. Mineralization of pH-sensitive doxorubicin prodrug in ZIF-8 to allow focused supply to stable tumors. Anal Chem. 2020;92:11453–61.
Yao T, Feng J, Chu C, Ma Z, Han H. Cascade managed launch system based mostly on pH-responsive ZIF-8 capsule and enzyme-responsive hyaluronic acid hydrogel for tumor marker detection utilizing electro-readout-mode. Sens Actuators B Chem. 2021;348: 130701.
Wu S, Zhang Ok, Liang Y, Wei Y, An J, Wang Y, Yang J, Zhang H, Zhang Z, Liu J, Shi J. Nano-enabled tumor systematic power exhaustion through zinc (II) interference mediated glycolysis inhibition and particular GLUT1 depletion. Adv Sci. 2022;9:2270045.
Liu W, Semcheddine F, Guo Z, Jiang H, Wang X. Glucose-responsive ZIF-8 nanocomposites for focused most cancers remedy by combining hunger with stimulus-responsive nitric oxide synergistic remedy. ACS Appl Bio Mater. 2022;5:2902–12.
Solar D, Qi G, Ma Ok, Qu X, Xu W, Xu S, Jin Y. Tumor microenvironment-activated degradable multifunctional nanoreactor for synergistic most cancers remedy and glucose SERS suggestions. iScience. 2020;23:101274.
Li F, Chen T, Wang F, Chen J, Zhang Y, Track D, Li N, Lin X-H, Lin L, Zhuang J. Enhanced most cancers hunger remedy enabled by an autophagy inhibitors-encapsulated biomimetic ZIF-8 nanodrug: disrupting and harnessing twin pro-survival autophagic responses. ACS Appl Mater Interfaces. 2022;14:21860–71.
Wang J, Yao L, Hu E, Cui Y, Yang D, Qian G. MnO2 adorned ZIF-8@GOx for synergistic chemodynamic and hunger remedy of most cancers. J Stable State Chem. 2021;298: 122102.
Shao F, Wu Y, Tian Z, Liu S. Biomimetic nanoreactor for focused most cancers hunger remedy and cascade amplificated chemotherapy. Biomaterials. 2021;274: 120869.
Wang W, Zhang L, Deng Q, Liu Z, Ren J, Qu X. Yeast@MOF bioreactor as a tumor metabolic symbiosis disruptor for the potent inhibition of metabolically heterogeneous tumors. Nano Right this moment. 2022;42: 101331.
Zhou X, Zhao W, Wang M, Zhang S, Li Y, Hu W, Ren L, Luo S, Chen Z. Twin-modal therapeutic position of the lactate oxidase-embedded hierarchical porous zeolitic imidazolate framework as a nanocatalyst for efficient tumor suppression. ACS Appl Mater Interfaces. 2020;12:32278–88.
Yu J, Wei Z, Li Q, Wan F, Chao Z, Zhang X, Lin L, Meng H, Tian L. Superior most cancers hunger remedy by simultaneous deprivation of lactate and glucose utilizing a MOF nanoplatform. Adv Sci (Weinh). 2021;8: e2101467.
Maret W. The redox biology of redox-inert zinc ions. Free Radic Biol Med. 2019;134:311–26.
Wan X, Track L, Pan W, Zhong H, Li N, Tang B. Tumor-targeted cascade nanoreactor based mostly on metal-organic frameworks for synergistic ferroptosis-starvation anticancer remedy. ACS Nano. 2020;14:11017–28.
Wang X, Zhao Y, Shi L, Hu Y, Track G, Cai Ok, Li M, Luo Z. Tumor-targeted disruption of lactate transport with reactivity-reversible nanocatalysts to amplify oxidative harm. Small. 2021;17:2100130.
Komkova MA, Karyakina EE, Karyakin AA. Catalytically synthesized prussian blue nanoparticles defeating pure enzyme peroxidase. J Am Chem Soc. 2018;140:11302–7.
Wang X, Cheng L. Multifunctional Prussian blue-based nanomaterials: preparation, modification, and theranostic purposes. Coord Chem Rev. 2020;419: 213393.
Liu Ok, Yan S, Liu Z, Wang D, Yang Q, Jiang X, Chen L, Tang H. New anti-tumor technique based mostly on acid-triggered self-destructive and near-infrared laser gentle responses of nano-biocatalysts integrating hunger—chemo–photothermal therapies. Most cancers Nanotechnol. 2022;13:11.
Wang Y, Track M. pH-responsive cascaded nanocatalyst for synergistic like-starvation and chemodynamic remedy. Colloids Surf B. 2020;192: 111029.
Lyu M, Zhu D, Kong X, Yang Y, Ding S, Zhou Y, Quan H, Duo Y, Bao Z. Glutathione-depleting nanoenzyme and glucose oxidase mixture for hypoxia modulation and radiotherapy enhancement. Adv Healthc Mater. 2020;9:1901819.
Ding X-L, Liu M-D, Cheng Q, Guo W-H, Niu M-T, Huang Q-X, Zeng X, Zhang X-Z. Multifunctional liquid metal-based nanoparticles with glycolysis and mitochondrial metabolism inhibition for tumor photothermal remedy. Biomaterials. 2022;281: 121369.
Xu L, Tong G, Track Q, Zhu C, Zhang H, Shi J, Zhang Z. Enhanced intracellular Ca2+ nanogenerator for tumor-specific synergistic remedy through disruption of mitochondrial Ca2+ homeostasis and photothermal remedy. ACS Nano. 2018;12:6806–18.
Dong Z, Feng L, Hao Y, Li Q, Chen M, Yang Z, Zhao H, Liu Z. Synthesis of CaCO3-based nanomedicine for enhanced sonodynamic remedy through amplification of tumor oxidative stress. Chem. 2020;6:1391–407.
Wu J, Liu T, Rios Z, Mei Q, Lin X, Cao S. Warmth shock proteins and most cancers. Traits Pharmacol Sci. 2017;38:226–56.
Ali MRK, Ali HR, Rankin CR, El-Sayed MA. Concentrating on warmth shock protein 70 utilizing gold nanorods enhances most cancers cell apoptosis in low dose plasmonic photothermal remedy. Biomaterials. 2016;102:1–8.
Gao G, Jiang Y-W, Guo Y, Jia HR, Cheng X, Deng Y, Yu XW, Zhu YX, Guo HY, Solar W, et al. Enzyme-mediated tumor hunger and phototherapy improve mild-temperature photothermal remedy. Adv Func Mater. 2020;30:1909391.
Wang X, Li Y, Jia F, Cui X, Pan Z, Wu Y. Boosting nutrient starvation-dominated most cancers remedy by curcumin-augmented mitochondrial Ca(2+) overload and obatoclax-mediated autophagy inhibition as supported by a novel nano-modulator GO-Alg@CaP/CO. J Nanobiotechnology. 2022;20:225.
Zeng Y, Zhou H, Ding J, Zhou W. Cell membrane impressed nano-shell enabling long-acting glucose oxidase for melanoma hunger remedy through microneedles-based percutaneous supply. Theranostics. 2021;11:8270–82.
Zhang C, Ni D, Liu Y, Yao H, Bu W, Shi J. Magnesium silicide nanoparticles as a deoxygenation agent for most cancers hunger remedy. Nat Nanotechnol. 2017;12:378–86.
Tang J, Meka AK, Theivendran S, Wang Y, Yang Y, Track H, Fu J, Ban W, Gu Z, Lei C, et al. Openwork@dendritic mesoporous silica nanoparticles for lactate depletion and tumor microenvironment regulation. Angew Chem Int Ed. 2020;59:22054–62.
Gao F, Tang Y, Liu W-L, Zou M-Z, Huang C, Liu C-J, Zhang X-Z. Intra/extracellular lactic acid exhaustion for synergistic metabolic remedy and immunotherapy of tumors. Adv Mater. 2019;31:1904639.
Fang X-L, Akrofi R, Yang H, Chen Q-Y. The NIR impressed nano-CuSMn(II) composites for lactate and glycolysis attenuation. Colloids Surf, B. 2019;181:728–33.
Li Ok, Lin C, He Y, Lu L, Xu Ok, Tao B, Xia Z, Zeng R, Mao Y, Luo Z, Cai Ok. Engineering of cascade-responsive nanoplatform to inhibit lactate efflux for enhanced tumor chemo-immunotherapy. ACS Nano. 2020;14:14164–80.
He R, Zang J, Zhao Y, Liu Y, Ruan S, Zheng X, Chong G, Xu D, Yang Y, Yang Y, et al. Nanofactory for metabolic and chemodynamic remedy: pro-tumor lactate trapping and anti-tumor ROS transition. J Nanobiotechnology. 2021;19:426.
Pei P, Shen W, Zhang Y, Zhang Y, Qi Z, Zhou H, Liu T, Solar L, Yang Ok. Radioactive nano-oxygen generator improve anti-tumor radio-immunotherapy by regulating tumor microenvironment and decreasing proliferation. Biomaterials. 2022;280: 121326.
Liu Y, Jiang Y, Zhang M, Tang Z, He M, Bu W. Modulating hypoxia through nanomaterials chemistry for environment friendly remedy of stable tumors. Acc Chem Res. 2018;51:2502–11.
Li Y, Jeon J, Park JH. Hypoxia-responsive nanoparticles for tumor-targeted drug supply. Most cancers Lett. 2020;490:31–43.
Kumari R, Sunil D, Ningthoujam RS. Hypoxia-responsive nanoparticle based mostly drug supply methods in most cancers remedy: an up-to-date evaluate. J Management Launch. 2020;319:135–56.
Dai Z, Wang Q, Tang J, Qu R, Wu M, Li H, Yang Y, Zhen X, Yu C. A Sub-6 nm MnFe2O4-dichloroacetic acid nanocomposite modulates tumor metabolism and catabolism for reversing tumor immunosuppressive microenvironment and boosting immunotherapy. Biomaterials. 2022;284: 121533.
Kolb D, Kolishetti N, Surnar B, Sarkar S, Guin S, Shah AS, Dhar S. Metabolic modulation of the tumor microenvironment results in a number of checkpoint inhibition and immune cell infiltration. ACS Nano. 2020;14:11055–66.
Yu W, Lin R, He X, Yang X, Zhang H, Hu C, Liu R, Huang Y, Qin Y, Gao H. Self-propelled nanomotor reconstructs tumor microenvironment by synergistic hypoxia alleviation and glycolysis inhibition for promoted anti-metastasis. Acta Pharm Sinica B. 2021;11:2924–36.
Liu X, Li Y, Wang Ok, Chen Y, Shi M, Zhang X, Pan W, Li N, Tang B. GSH-responsive nanoprodrug to inhibit glycolysis and alleviate immunosuppression for most cancers remedy. Nano Lett. 2021;21:7862–9.
Li F, Zhang R, Li S, Liu J. IDO1: an necessary immunotherapy goal in most cancers remedy. Int Immunopharmacol. 2017;47:70–7.
Nayak A, Hao Z, Sadek R, Vahanian N, Ramsey WJ, Kennedy E, Mautino M, Hyperlink C, Bourbo P, Dobbins R, et al. A part I research of NLG919 for grownup sufferers with recurrent superior stable tumors. J Immunother Most cancers. 2014;2:P250.
Liu X, Shin N, Koblish HK, Yang G, Wang Q, Wang Ok, Leffet L, Hansbury MJ, Thomas B, Rupar M, et al. Selective inhibition of IDO1 successfully regulates mediators of antitumor immunity. Blood. 2010;115:3520–30.
Solar F, Zhu Q, Li T, Saeed M, Xu Z, Zhong F, Track R, Huai M, Zheng M, Xie C, et al. Regulating glucose metabolism with prodrug nanoparticles for selling photoimmunotherapy of pancreatic most cancers. Adv Sci. 2021;8:2002746.
Devaiah BN, Mu J, Akman B, Uppal S, Weissman JD, Cheng D, Baranello L, Nie Z, Levens D, Singer DS. MYC protein stability is negatively regulated by BRD4. Proc Natl Acad Sci. 2020;117:13457–67.
Liu X, Wu H, Huang P, Zhang F. JQ1 and PI3K inhibition synergistically cut back salivary adenoid cystic carcinoma malignancy by focusing on the c-Myc and EGFR signaling pathways. J Oral Pathol Med. 2019;48:43–51.
Jing X, Shao S, Zhang Y, Luo A, Zhao L, Zhang L, Gu S, Zhao X. BRD4 inhibition suppresses PD-L1 expression in triple-negative breast most cancers. Exp Cell Res. 2020;392: 112034.
Yang FR, Zhao YF, Hu XW, Liu ZK, Yu XD, Li CY, Li XR, Li HJ. Nano-realgar suppresses lung most cancers stem cell development by repressing metabolic reprogramming. Gene. 2021;788: 145666.
Gu Z, Liu T, Liu C, Yang Y, Tang J, Track H, Wang Y, Yang Y, Yu C. Ferroptosis-strengthened metabolic and inflammatory regulation of tumor-associated macrophages provokes potent tumoricidal actions. Nano Lett. 2021;21:6471–9.
Cassetta L, Pollard JW. Concentrating on macrophages: therapeutic approaches in most cancers. Nat Rev Drug Discov. 2018;17:887–904.
Wenes M, Shang M, Di Matteo M, Goveia J, Martín-Pérez R, Serneels J, Prenen H, Ghesquière B, Carmeliet P, Mazzone M. Macrophage metabolism controls tumor blood vessel morphogenesis and metastasis. Cell Metab. 2016;24:701–15.
Zhao S, Peralta RM, Avina-Ochoa N, Delgoffe GM, Kaech SM. Metabolic regulation of T cells within the tumor microenvironment by nutrient availability and weight-reduction plan. Semin Immunol. 2021;52: 101485.
Kato Y, Ozawa S, Miyamoto C, Maehata Y, Suzuki A, Maeda T, Baba Y. Acidic extracellular microenvironment and most cancers. Most cancers Cell Int. 2013;13:89.
Miranda-Gonçalves V, Granja S, Martinho O, Honavar M, Pojo M, Costa BM, Pires MM, Pinheiro C, Cordeiro M, Bebiano G, et al. Hypoxia-mediated upregulation of MCT1 expression helps the glycolytic phenotype of glioblastomas. Oncotarget. 2016;7:46335–53.
Pérez de Heredia F, Wooden IS, Trayhurn P. Hypoxia stimulates lactate launch and modulates monocarboxylate transporter (MCT1, MCT2, and MCT4) expression in human adipocytes. Pflügers Arch. 2010;459:509–18.
Takagi H, King GL, Aiello LP. Hypoxia upregulates glucose transport exercise by an adenosine-mediated improve of GLUT1 expression in retinal capillary endothelial cells. Diabetes. 1998;47:1480–8.
Meijer TW, Schuurbiers OC, Kaanders JH, Looijen-Salamon MG, de Geus-Oei LF, Verhagen AF, Lok J, van der Heijden HF, Rademakers SE, Span PN, Bussink J. Variations in metabolism between adeno- and squamous cell non-small cell lung carcinomas: spatial distribution and prognostic worth of GLUT1 and MCT4. Lung Most cancers. 2012;76:316–23.
Neugent ML, Goodwin J, Sankaranarayanan I, Yetkin CE, Hsieh MH, Kim JW. A brand new perspective on the heterogeneity of most cancers glycolysis. Biomol Ther (Seoul). 2018;26:10–8.
Monti S, Savage KJ, Kutok JL, Feuerhake F, Kurtin P, Mihm M, Wu B, Pasqualucci L, Neuberg D, Aguiar RCT, et al. Molecular profiling of diffuse giant B-cell lymphoma identifies strong subtypes together with one characterised by host inflammatory response. Blood. 2005;105:1851–61.
Faubert B, Solmonson A, DeBerardinis RJ. Metabolic reprogramming and most cancers development. Science. 2020;368:eaaw5473.
Warmoes MO, Locasale JW. Heterogeneity of glycolysis in cancers and therapeutic alternatives. Biochem Pharmacol. 2014;92:12–21.
Biswas Subhra Ok. Metabolic reprogramming of immune cells in most cancers development. Immunity. 2015;43:435–49.
Nayak AP, Kapur A, Barroilhet L, Patankar MS. Oxidative phosphorylation: a goal for novel therapeutic methods towards ovarian most cancers. Cancers (Basel). 2018;10:337.
Liu J, Chen T, Yang M, Zhong Z, Ni S, Yang S, Shao F, Cai L, Bai J, Yu H. Improvement of an oxidative phosphorylation-related and immune microenvironment prognostic signature in uterine corpus endometrial carcinoma. Entrance Cell Dev Biol. 2021;9: 753004.
LeBleu VS, O’Connell JT, Gonzalez Herrera KN, Wikman H, Pantel Ok, Haigis MC, de Carvalho FM, Damascena A, Domingos Chinen LT, Rocha RM, et al. PGC-1α mediates mitochondrial biogenesis and oxidative phosphorylation in most cancers cells to advertise metastasis. Nat Cell Biol. 2014;16(992–1003):1001–15.
Marcucci F, Rumio C. Glycolysis-induced drug resistance in tumors—a response to hazard alerts? Neoplasia. 2021;23:234–45.
Bian W, Wang Y, Pan Z, Chen N, Li X, Wong WL, Liu X, He Y, Zhang Ok, Lu YJ. Overview of functionalized nanomaterials for photothermal remedy of cancers. ACS Appl Nano Mater. 2021;4:11353–85.
Shen Z, Ma Q, Zhou X, Zhang G, Hao G, Solar Y, Cao J. Methods to enhance photodynamic remedy efficacy by relieving the tumor hypoxia setting. NPG Asia Mater. 2021;13:39.
Tang Z, Liu Y, He M, Bu W. Chemodynamic remedy: tumour microenvironment-mediated fenton and fenton-like reactions. Angew Chem Int Ed. 2019;58:946–56.
